GF
ALXN

Gabelli Funds’s Alexion Pharmaceuticals ALXN Stock Holding History

Gabelli Funds’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-295,915
Closed -$54.4M – 1501
2021
Q2 		$54.4M Buy
295,915
+43,500
+17% +$7.47M 0.35% 72
2021
Q1 		$38.6M Buy
252,415
+139,714
+124% +$21.6M 0.26% 106
2020
Q4 		$17.6M Buy
112,701
+71,701
+175% +$9.21M 0.13% 209
2020
Q3 		$4.69M Hold
41,000
– – 0.04% 455
2020
Q2 		$4.6M Hold
41,000
– – 0.04% 452
2020
Q1 		$3.68M Sell
41,000
-10,000
-20% -$981K 0.03% 482
2019
Q4 		$5.52M Sell
51,000
-5,000
-9% -$535K 0.04% 479
2019
Q3 		$5.49M Buy
56,000
+5,000
+10% +$564K 0.04% 485
2019
Q2 		$6.68M Buy
51,000
+2,500
+5% +$322K 0.04% 443
2019
Q1 		$6.56M Sell
48,500
-3,900
-7% -$485K 0.04% 453
2018
Q4 		$5.1M Buy
52,400
+17,400
+50% +$2.06M 0.04% 499
2018
Q3 		$4.87M Sell
35,000
-1,000
-3% -$125K 0.03% 578
2018
Q2 		$4.47M Sell
36,000
-11,500
-24% -$1.34M 0.03% 598
2018
Q1 		$5.29M Buy
47,500
+13,300
+39% +$1.59M 0.03% 542
2017
Q4 		$4.09M Buy
34,200
+23,000
+205% +$2.8M 0.02% 616
2017
Q3 		$1.57M Sell
11,200
-9,800
-47% -$1.33M 0.01% 832
2017
Q2 		$2.56M Buy
+21,000
New +$2.44M 0.02% 715
2015
Q3 		– Sell
-1,316
Closed -$238K – 1109
2015
Q2 		$238K Buy
+1,316
New +$227K ﹤0.01% 1036

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Gabelli Funds's ALXN Position: Q3 2021 in Review

Gabelli Funds sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 295,915 shares — an estimated $54.4M sold.

Gabelli Funds first reported a position in ALXN in Q2 2015 and held it in 18 quarters. The position peaked at $54.4M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Gabelli Funds reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Gabelli Funds sold 295,915 Alexion Pharmaceuticals shares in Q3 2021, an estimated $54.4M.
  • Gabelli Funds first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 18 quarters.
  • Gabelli Funds's Alexion Pharmaceuticals position peaked at $54.4M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Gabelli Funds's 13F filing for Q3 2021, filed 12 Nov 2021.